<DOC>
	<DOCNO>NCT00934895</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop dividing . Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving paclitaxel albumin-stabilized nanoparticle formulation together everolimus may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose everolimus give together paclitaxel albumin-stabilized nanoparticle formulation see well work treat woman locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Phase I/II Study Weekly Abraxane RAD001 Women With Locally Adv . Metastatic Breast Ca</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose recommend phase II dose everolimus administer combination paclitaxel albumin-stabilized nanoparticle formulation woman locally advance metastatic breast cancer . ( Phase I ) - To determine antitumor activity regimen , measure clinical tumor response accord RECIST criterion , patient . ( Phase II ) Secondary - To determine safety tolerability everolimus administer recommended phase II dose combination paclitaxel albumin-stabilized nanoparticle formulation patient . OUTLINE : This multicenter , phase I dose-escalation study everolimus follow phase II study . Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 , 8 , 15 . Patients also receive oral everolimus daily every day day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Locally recurrent metastatic disease Not amenable surgery radiotherapy HER2/neunegative disease Has ≥ 1 measurable lesion , define RECIST criterion No nonmeasurable lesion ( e.g. , pleural effusion ascites ) bone metastases Bone metastases sole site disease allow provide ≥ 2 lytic bone lesion xray , CT scan , MRI Lesions irradiate advanced setting consider site measurable disease unless clear tumor progression document lesion since completion radiotherapy No bilateral diffuse lymphangitis carcinomatosa lung ( &gt; 50 % lung involvement ) evidence liver metastasis estimate involve &gt; one third liver sonogram and/or CT scan No unstable CNS metastases Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy ≥ 3 month ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin &gt; 9 g/dL Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN patient liver metastasis ) INR &lt; 1.5 time ULN Serum creatinine ≤ 1.5 mg/dL Fasting serum cholesterol ≤ 300 mg/dL ( 7.75 mmol/L ) ( level outside threshold allow provide statin therapy initiate ) Fasting triglyceride ≤ 2.5 time ULN ( level outside threshold allow provide statin therapy initiate ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Oral , implantable , injectable contraceptive consider effective contraception No ascites encephalopathy due liver disease No neuropathy ≥ grade 2 No impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption everolimus , include follow : Ulcerative disease Uncontrolled nausea , vomit , diarrhea Malabsorption syndrome No active , bleed diathesis No known HIV seropositivity No known hypersensitivity everolimus sirolimus ( rapamycin ) , paclitaxel albuminstabilized nanoparticle formulation , lactose No history noncompliance medical regimens No severe and/or uncontrolled medical condition condition could affect study participation , include follow : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within past 6 month , serious uncontrolled cardiac arrhythmia Severely impaired lung function Active ( acute chronic ) uncontrolled infection disorder Nonmalignant medical illness uncontrolled whose control may jeopardize study treatment Liver disease ( e.g. , cirrhosis , chronic active hepatitis , chronic persistent hepatitis ) No malignancy within past 5 year , except curatively treat carcinoma situ cervix nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Prior systemic endocrine therapy advance breast cancer allow No prior chemotherapy advance breast cancer Prior adjuvant chemotherapy allow No prior small bowel resection More 5 day since prior strong CYP3A inhibitor inducer ( e.g. , rifabutin , rifampin , clarithromycin , ketoconazole , itraconazole , voriconazole , ritonavir , telithromycin ) More 30 day since prior radiotherapy recover ( alopecia allow ) Prior localize radiotherapy analgesic purpose allow provided radiotherapy complete patient 's condition stabilize No prior radiotherapy ≥ 25 % bone marrow More 30 day since prior investigational drug More 1 week since prior concurrent immunization attenuate live vaccine No concurrent oral antivitamin K medication , except lowdose coumadin No concurrent systemic steroid immunosuppressive agent chronic therapy Topical application , inhale spray , eye drop , local injection allow A short duration ( &lt; 2 week ) systemic corticosteroid allow No concurrent hormone replacement therapy , topical estrogen ( include intravaginal preparation ) , megestrol acetate , selective estrogenreceptor modulators ( e.g. , raloxifene ) No concurrent investigational anticancer agent Concurrent antiangiogenic agent allow Concurrent bisphosphonates allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>